Norio Hamamatsu

USPTO Granted Patents = 9 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 111(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11944664 - Fibroblast growth factor-21-Fc fusion proteins (2024-04-02),

2. 11312766 - Antibodies against growth differentiation factor 15 and uses thereof (2022-04-26),

3. 11129874 - Nucleic acids encoding FGF21-Fc fusion proteins (2021-09-28),

4. 10669323 - Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins (2020-06-02),

5. 10076554 - FGF21-FC fusion proteins for treating metabolic disorders (2018-09-18),

6. 9458214 - Dual function fibroblast growth factor 21 proteins (2016-10-04),

7. 9266935 - Methods of treating metabolic disorders with an FGF21 variant (2016-02-23),

8. 9023791 - Fibroblast growth factor 21 mutations (2015-05-05),

9. 9006400 - Fibroblast growth factor-21-Fc fusion proteins (2015-04-14),

Title: Norio Hamamatsu: Innovator in Biomedical Research

Introduction

Norio Hamamatsu is a distinguished inventor based in Belmont, MA (US). He has made significant contributions to the field of biomedical research, holding a total of 9 patents. His work primarily focuses on developing innovative therapeutic solutions for various medical conditions.

Latest Patents

One of his latest patents is for "Fibroblast growth factor-21-Fc fusion proteins." This invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. The patent also discloses methods for treating FGF21-associated disorders, including metabolic conditions. Another notable patent is for "Antibodies against growth differentiation factor 15 and uses thereof." This patent provides monoclonal antibodies, including human antibodies, that bind to human Growth Differentiation Factor 15 protein (GDF15), along with pharmaceutical compositions and treatment methods.

Career Highlights

Norio has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Irm LLC. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Norio has collaborated with notable professionals, including Brian R. Boettcher and Shari Lynn Caplan. These collaborations have further enhanced his research and innovation efforts.

Conclusion

Norio Hamamatsu's contributions to biomedical research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.